ALPMY News and Press, Astellas Pharma Inc. ADR From 05/06/19

Cytokinetics (NASDAQ: CYTK ) slumps  15%  premarket on light volume in reaction to unsuccessful results from a Phase 2 clinical trial, FORTITUDE-ALS , evaluating reldesemtiv (CK-2127107) in patients with amyotrophic lateral sclerosis (ALS). More news on: Cytokinetics, Incorpor...

CHICAGO , May 5, 2019 /PRNewswire/ -- Astellas Pharma Inc. today announced results from the Phase 4, 12-week PLUS trial, the first large-scale, randomized trial in North America and Europe evaluating the efficacy and safety of mirabegron vs. placebo in men with overactive bladder...

Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c...

The U.S. Department of Justice (DOJ)  announces settlements with Astellas Pharma ( OTCPK:ALPMY -2.9% ) and Amgen ( AMGN +0.7% ) over their alleged kickback schemes aimed at illegally paying Medicare beneficiaries' copays for certain medications. More news on: Astellas Pharma Inc....

NORTHBROOK, Ill. , April 3, 2019 /PRNewswire/ -- Astellas is pleased to announce two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. Steven Benner , M.D., was promoted to president and Head of Development; Zhonghong Eric Gu...

Thinly traded micro cap Constellation Pharmaceuticals ( CNST -1.4% ) slips on average volume in response to results from the Phase 1b portion of a Phase 1/2 clinical trial, ProSTAR , evaluating CPI-1205, combined with Pfizer and Astellas' Xtandi (enzalutamide) or J & J's Zytiga (abi...

TOKYO , April 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa , Ph.D. "Astellas") today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA ® (gilteritinib) to salvage chemotherapy in adult patients with relapsed o...

By Bill Langbein, Founder SanaCurrents One of the strongest performing biopharmaceutical stocks this year is Evolus ( EOLS ). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then ...

BOTHELL, Wash. and TOKYO , March 28, 2019 /PRNewswire/ --  Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced positive topline results from the first cohort of patients in a...

TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract OR33-6 ) at ENDO 2019, the Endocr...